Oppenheimer analyst Andreas Argyrides lowered the price target on Rani Therapeutics Holdsing s (NASDAQ: RANI) to $4.00 (from $14.00) while ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE